Silo Wellness Inc

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

Silo Pharma Announces Share Buyback Program

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD